Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 3912-3916

  Soucy, Teresa A ^a   Smith, Peter G ^a   Rolfe, Mark ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

26S PROTEASOME; BETA CATENIN; BORTEZOMIB; CULLIN; CULLIN 1; CULLIN 3; CULLIN RING UBIQUITIN E3 LIGASE; CYCLIN E; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B ALPHA; IMIDAZOLINE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MLN 4924; MYC PROTEIN; NEDD8 ACTIVATING ENZYME; NEDD8 PROTEIN; PROTEASOME; PROTEIN C JUN; PROTEIN MDM2; PROTEIN P27; PROTEIN P53; SUMO PROTEIN; TRANSCRIPTION FACTOR NRF2; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON HIPPEL LINDAU PROTEIN;

ANTINEOPLASTIC ACTIVITY; CELL SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME MECHANISM; HEMATOLOGIC MALIGNANCY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; REVIEW; SOLID TUMOR; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CULLIN PROTEINS; CYCLOPENTANES; HUMANS; NEOPLASMS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; PYRIMIDINES; RING FINGER DOMAINS; SIGNAL TRANSDUCTION; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 67449119401     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0343     Document Type: Review

References (53)

1. Reinstein E, Ciechanover A. Narrative review: protein degradation and human disease: the ubiquitin connection. Ann Intern Med 2006;145:676-684, PubMed. (Pubitemid 46768844)
2. Ciechanover A. Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin proteasome system and onto human diseases and drug targeting. Cell Death Differ 2005;12:1178-1190, PubMed doi:10.1038/sj.cdd.4401692.
3. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-479, PubMed doi:10.1146/annurev.biochem.67.1.425. (Pubitemid 28411135)
4. Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ 2005;12:1191-1197, PubMed doi:10.1038/sj.cdd.4401702. (Pubitemid 41195103)
5. Haas AL, Rose IA. The mechanism of ubiquitin activating enzyme: A kinetic and equilibrium analysis. J Biol Chem 1982;257:10329-10337, PubMed.
6. Ardley HC, Robinson PA. E3 ubiquitin ligases. Essays Biochem 2005;41:15-30, PubMed doi:10.1042/EB0410015. (Pubitemid 41500968)
7. Kee Y, Huibregtse JM. Regulation of catalytic activities of HECT ubiquitin ligases. Biochem Biophys Res Commun 2007;354:329-333, PubMed doi:10.1016/j.bbrc.2007.01.025. (Pubitemid 46161353)
8. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther 2003;2:623-629, PubMed.
9. Willems AR, Schwab M, Tyers M. A hitchhikers guide to the cullin ubiquitin ligases: SCF and its kin. Biochim Biophys Acta 2004;1695:133-170 (Pubitemid 39574971)
10. Hatakeyama S, Nakayama KI. U-box proteins as a new family of ubiquitin ligases. Biochem Biophys Res Commun 2003;302:635-45, PubMed doi:10.1016/S0006- 291X(03)00245-246 (Pubitemid 36294020)
11. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin proteasome system. Nat Rev Drug Discov 2006;5:596-613, PubMed doi:10.1038/nrd2056. (Pubitemid 43971194)
12. Richardson PG, Barlogie B, Berenson J, et al. A Phase 2 Study of Bortezomib in relapsed refractory myeloma. N Engl J Med 2003;348:2609-2617, PubMed doi:10.1056/NEJMoa030288. (Pubitemid 36741588)
13. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007;13:5291-4, PubMed doi:10.1158/1078-0432.CCR-07-0871. (Pubitemid 47510352)
14. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1649, doi:10.1158/1078-0432.CCR- 07-2218.
15. Demo SD, Kirk CJ, Aujay MA, et al. Anti-tumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-91, PubMed doi:10.1158/0008-5472.CAN-06-4086. (Pubitemid 47037522)
16. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006;22:159-180, PubMed doi:10.1146/annurev.cellbio.22.010605.093503. (Pubitemid 44777993)
17. Pan ZQ, Kentsis A, Dias DC, Yamoah K, Wu K. NEDD8 on cullin: building an expressway to protein destruction. Oncogene 2004;23:1985-1997, PubMed doi:10.1038/sj.onc.1207414. (Pubitemid 38496728)
18. Geiss-Friedlander R, Melchior F. Concepts in sumoylation a decade on. Nat Rev Mol Cell Biol 2007;8:947-956, PubMed doi:10.1038/nrm2293. (Pubitemid 350176509)
19. Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptions. Nat Cell Biol 2007;9:1102-1109, PubMed doi:10.1038/ncb1007-1102. (Pubitemid 47500484)
20. Andersen JB, Hassel BA. The interferon regulated ubiquitin-like protein ISG15 in tumorigenesis, friend or foe? Cytokine Growth Factor Rev 2006;17:411-421, PubMed doi:10.1016/j.cytogfr.2006.10.001. (Pubitemid 44793124)
21. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005;6:9-20, PubMed doi:10.1038/nrm1547.
22. Zheng N, Schulman BA, Song L, et al. Structure of the Cul1-Rbx1-Skp1-FboxSkp2 SCF ubiquitin ligase complex. Nature 2002;416:703-709, PubMed doi:10.1038/416703a. (Pubitemid 34429140)
23. Podust VN, Brownell JE, Gladysheva TB, et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci U S A 2000;97:4579-4584, PubMed doi:10.1073/pnas.090465597. (Pubitemid 30238600)
24. Read MA, Brownell JE, Gladysheva TB, et al. Nedd8 modification of cul-1 activates SCF(beta (TrCP))-dependent ubiquitination of Ikappa-Balpha. Mol Cell Biol 2000;20:2326-2333, PubMed doi:10.1128/MCB.20.7.2326-2333.2000. (Pubitemid 30152040)
25. Gong L, Yeh ET. Identification of the activating and conjugating enzymes of the NEDD8 pathway. J Biol Chem 1999;274:12036-12042, PubMed doi:10.1074/jbc.274.17.12036. (Pubitemid 129518465)
26. Kurz T, Chou Y-C, Willems AR, et al. Dcn1 functions as a scaffold-type E3 ligase for cullin neddylation. Mol Cell 2008;29:23-35, PubMed doi: 10.1016/j.molcel.2007.12.012.
27. Kim AY, Bommeljé CC, Lee BE, et al. SCCRO (DCUN1D1) is an essential component of the E3 complex for neddylation. J Biol Chem 2008;283:33211-33220
28. Kawakami T, Chiba T, Suzuki T, et al. NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J 2001;20:4003-4012, PubMed doi:10.1093/emboj/20.15.4003. (Pubitemid 32751817)
29. Sakata E, Yamaguchi Y, Miyauchi Y, et al. Direct interactions between NEDD8 and ubiquitin E2 conjugating enzymes upregulate cullin-based E3 ligase activity. Nat Struct Mol Biol 2007;14:167-168, PubMed doi:10.1038/nsmb1191. (Pubitemid 46245804)
30. Duda DM, Borg LA, Scott DC, et al. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 2008;134:995-1006, PubMed doi:10.1016/j.cell.2008.07.022.
31. Wei N, Serino G, Deng X-W. The COP9 signalosome: more than a protease. Trends Biochem Sci 2008;33:592-600.
32. Zheng J, Yang X, Harrell JM, et al. CAND1 binds to unneddylated Cul1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol Cell 2002;10:1519-26, PubMed doi:10.1016/S1097-2765(02)00784-790 (Pubitemid 36050892)
33. Bornstein G, Ganoth D, Hershko A. Regulation of neddylation and deneddylation of cullin1 in SCFSkp2 ubiquitin ligase by F-box protein and substrate. Proc Natl Acad Sci U S A 2006;103:11515-11520, PubMed doi:10.1073/pnas.0603921103. (Pubitemid 44182483)
34. Lo SC, Hannink M. CAND1-mediated substrate adaptor recycling is required for efficient repression of Nrf2 by Keap1. Mol Cell Biol 2006;26:1235-1244, PubMed doi:10.1128/MCB.26.4.1235-1244.2006. (Pubitemid 43202552)
35. Wee S, Geyer RK, Toda T, et al. CSN facilitates cullin-RING ubiquitin ligase function by counteracting autocatalytic adaptor instability. Nat Cell Biol 2005;7:387-391, PubMed doi:10.1038/ncb1241. (Pubitemid 40533128)
36. Vassilev LT. Small molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 2004;3:419-421, PubMed. (Pubitemid 40278226)
37. Zhang, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des 2000;6:393-416, PubMed doi:10.2174/1381612003400911.
38. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small molecule antagonists of MDM2. Science 2004;303:844-848, PubMed doi:10.1126/science.1092472.
39. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-736
40. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511, PubMed doi:10.1038/35000501. (Pubitemid 30082188)
41. Feuerhake F, Kutok JL, Monti S, et al. NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005;106:1392-9, PubMed doi:10.1182/blood-2004-12-4901. (Pubitemid 41129606)
42. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309, PubMed doi:10.1038/nrc1588. (Pubitemid 40488635)
43. Miranda-Carboni GA, Krum SA, Yee K, et al. A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. Genes Dev 2008;22:3121-3134, PubMed doi:10.1101/gad.1692808.
44. Dehan E, Bassermann F, Guardavaccaro D, et al. βTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell 2009;33:109-116, PubMed doi:10.1016/j.molcel.2008.12.020.
45. Tsvetkov LM, Yeh KH, Lee SJ, et al. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9:661-4, PubMed doi:10.1016/S0960-9822(99)80290-5
46. Winston JT, Strack P, Beer-Romero P, et al. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 1999;13:270-283, PubMed doi:10.1101/gad.13.3.270. (Pubitemid 29095799)
47. Koepp DM, Schaefer LK, Ye X. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001;294:173-177, PubMed doi:10.1126/science.1065203. (Pubitemid 32952972)
48. Yada M, Hatakeyama S, Kamura T. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004;23:2116-25, PubMed doi:10.1038/sj.emboj. 7600217. (Pubitemid 38737738)
49. Nateri AS, Riera-Sans L, DaCosta C, et al. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 2004;303:1374-1378, PubMed doi:10.1126/science.1092880. (Pubitemid 38269431)
50. Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008;321:1499-1502, doi:10.1126/science.1162981.
51. Liakopoulos D, Büsgen T, Brychzy A, et al. Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. Proc Natl Acad Sci U S A 1999;96:5510-5515, PubMed doi:10.1073/pnas.96.10.5510. (Pubitemid 29234648)
52. Kobayashi A, Kang MI, Okawa H, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004;24:7130-7139, PubMed doi:10.1128/MCB.24.16.7130-7139.2004. (Pubitemid 39014439)
53. Jin J, Arias EE, Chen J, et al. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell 2006;23:709-721, PubMed doi:10.1016/j.molcel. 2006.08.010. (Pubitemid 44292562)